PubMed Health⌕ Search

PubMed · 15317374

An update on ECMO.

Abstract

Extracorporeal membrane oxygenation (ECMO) is essentially a heart-lung bypass machine that can be used to support certain critically ill neonates. ECMO therapy reached a peak in usage in the mid to late 1980s. At that time, ECMO was most often used for severe complications of persistent pulmonary hypertension, meconium aspiration, congenital diaphragmatic hernia, and sepsis. Since that time, the use of ECMO has decreased, due largely to newer medical advances that have improved the course of these neonates. Whether a nurse works in a Level III ECMO center or a Level I, II, or III NICU, ECMO treatment has become less familiar than it once was. But even though ECMO is used less often, there are times when nothing can take its place. It is important to stay informed so that families of those critically ill newborns who do need ECMO can be educated and supported. This article defines ECMO, discusses when it should be incorporated into the plan of care, describes advances in the NICU that have resulted in the dramatic reduction in the use of ECMO, and provides information and communication strategies to better support the family of a very sick newborn.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dina R Tulenko. An update on ECMO.. https://doi.org/10.1891/0730-0832.23.4.11

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Extended use of extracorporeal membrane oxygenation after lung transplantation.

OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) for severe graft failure after lung transplantation is accepted immediately postoperatively; extending its use is controversial. We evaluated our post-lung transplant ECMO experience, which included extended indication, to (1) determine its prevalence, risk factors, indications, and timing, (2) compare complications and outcomes of these patients with those not requiring it, and (3) identify risk factors, including indications, for mortality. METHODS: From February 1990 to October 2005, 474 patients underwent lung transplantation; postoperative ECMO support was instituted for severe graft failure 23 times in 22 patients (4.0%). Indications for ECMO and its timing were obtained by reviewing medical records and survival by systematic follow-up. RESULTS: No factor evaluated predicted severe graft failure leading to ECMO. The most common indication for ECMO was early graft failure (13 patients); however, it was also used for pneumonia or sepsis (6) and acute rejection (4). ECMO was initiated at a median arterial oxygen tension/inspired oxygen fraction of 59 at a median of 2 days postoperatively and was maintained for a median of 4 days. The most common complications were renal failure (57%) and bleeding (43%). ECMO was effective in salvaging patients with rejection and early graft failure (survival at 1, 3, 6, and 12 months: 62%, 54%, 49%, and 41%), but ineffective for pneumonia or sepsis (survival at these intervals: 9%, 4%, 4%, and 3%). CONCLUSIONS: ECMO can be extended beyond early severe graft failure to acute rejection and can be considered after the immediate postoperative period. Survival after ECMO in patients with pneumonia or sepsis is poor.

Extracorporeal Membrane Oxygenation↗